Next article Search Articles Instructions for authors  Access Statistics | Citation Manager  
REVIEW ARTICLE  

 Article Access Statistics
    Viewed13657    
    Printed371    
    Emailed11    
    PDF Downloaded2087    
    Comments [Add]    
    Cited by others 18    

Recommend this journal


Click on image for details.

 Current status of bosentan for treatment of pulmonary hypertension

Shahzad G Raja, Gilles D Dreyfus
Harefield Hospital, Middlesex, United Kingdom

Correspondence Address:
Shahzad G Raja
Department of Cardiothoracic Surgery, Harefield Hospital, Hill End Road, Harefield, Middlesex, UB9 6JH
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0971-9784.38443

Rights and Permissions

Year : 2008  |  Volume : 11  |  Issue : 1  |  Page : 6-14

 
SEARCH
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles

  Article in PDF (135 KB)
Email article
Print Article
Add to My List
Pulmonary arterial hypertension (PAH) is a debilitating disease associated with significant morbidity and a high mortality if left untreated. Over the past 5 years, there have been significant advances with regard to the understanding of the pathogenesis, diagnosis and classification of PAH. The availability of newer drugs has resulted in a radical change in the management of this disease with significant improvement in both the quality of life and mortality. One of the recent drugs is an orally active dual endothelin receptor antagonist, bosentan; this drug has shown to improve the exercise capacity and survival in patients with PAH. This review article discusses the pharmacology of bosentan and summarises the current available evidence for the safety and efficacy of bosentan for the treatment of PAH.






[FULL TEXT] [PDF]*
 

 

  Sitemap | Feedback | Disclaimer | What's New |  
  © Annals of Cardiac Anaesthesia | Published by Wolters Kluwer - Medknow
 Online since 5th January, 2008

 

 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 
 
 Reader Comments
 Email Alert *
  *
 * Requires registration (Free)
 
 REVIEW ARTICLE
 



Shahzad G Raja, Gilles D Dreyfus
Harefield Hospital, Middlesex, United Kingdom

Correspondence Address:
Shahzad G Raja
Department of Cardiothoracic Surgery, Harefield Hospital, Hill End Road, Harefield, Middlesex, UB9 6JH
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0971-9784.38443

Rights and Permissions

Pulmonary arterial hypertension (PAH) is a debilitating disease associated with significant morbidity and a high mortality if left untreated. Over the past 5 years, there have been significant advances with regard to the understanding of the pathogenesis, diagnosis and classification of PAH. The availability of newer drugs has resulted in a radical change in the management of this disease with significant improvement in both the quality of life and mortality. One of the recent drugs is an orally active dual endothelin receptor antagonist, bosentan; this drug has shown to improve the exercise capacity and survival in patients with PAH. This review article discusses the pharmacology of bosentan and summarises the current available evidence for the safety and efficacy of bosentan for the treatment of PAH.






[FULL TEXT] [PDF]*


        
Print this article     Email this article  

  Sitemap | Feedback | Disclaimer | What's New |  
  © Annals of Cardiac Anaesthesia | Published by Wolters Kluwer - Medknow
 Online since 5th January, 2008